A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice

[1]  Morgan L. Maeder,et al.  Characterization of Staphylococcus aureus Cas9: a smaller Cas9 for all-in-one adeno-associated virus delivery and paired nickase applications , 2015, Genome Biology.

[2]  Y. Doyon,et al.  In vivo genome editing of the albumin locus as a platform for protein replacement therapy. , 2015, Blood.

[3]  James M. Wilson,et al.  Neonatal Systemic AAV Induces Tolerance to CNS Gene Therapy in MPS I Dogs and Nonhuman Primates. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  Martin J. Aryee,et al.  Engineered CRISPR-Cas9 nucleases with altered PAM specificities , 2015, Nature.

[5]  Zhiping Weng,et al.  Adenovirus-Mediated Somatic Genome Editing of Pten by CRISPR/Cas9 in Mouse Liver in Spite of Cas9-Specific Immune Responses. , 2015, Human gene therapy.

[6]  S. Beer-Hammer,et al.  In vivo genome editing using nuclease-encoding mRNA corrects SP-B deficiency , 2015, Nature Biotechnology.

[7]  David A. Scott,et al.  In vivo genome editing using Staphylococcus aureus Cas9 , 2015, Nature.

[8]  Florian Schmidt,et al.  CRISPR genome engineering and viral gene delivery: A case of mutual attraction , 2015, Biotechnology journal.

[9]  A. Parker,et al.  Evidence for Contribution of CD4+CD25+ Regulatory T Cells in Maintaining Immune Tolerance to Human Factor IX following Perinatal Adenovirus Vector Delivery , 2015, Journal of immunology research.

[10]  Martin J. Aryee,et al.  GUIDE-Seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases , 2014, Nature Biotechnology.

[11]  Yong Huang,et al.  Promoterless gene targeting without nucleases ameliorates haemophilia B in mice , 2014, Nature.

[12]  Feng Zhang,et al.  Genome engineering using CRISPR-Cas9 system. , 2015, Methods in molecular biology.

[13]  J. Doudna,et al.  The new frontier of genome engineering with CRISPR-Cas9 , 2014, Science.

[14]  Gang Wang,et al.  Targeted and genome-wide sequencing reveal single nucleotide variations impacting specificity of Cas9 in human stem cells , 2014, Nature Communications.

[15]  Pumin Zhang,et al.  Efficient gene editing in adult mouse livers via adenoviral delivery of CRISPR/Cas9 , 2014, FEBS letters.

[16]  M. Tuchman,et al.  A longitudinal study of urea cycle disorders. , 2014, Molecular genetics and metabolism.

[17]  E. Lander,et al.  Development and Applications of CRISPR-Cas9 for Genome Engineering , 2014, Cell.

[18]  Hao Yin,et al.  Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype , 2014, Nature Biotechnology.

[19]  Y. Doyon,et al.  Robust ZFN-mediated genome editing in adult hemophilic mice. , 2013, Blood.

[20]  R. Falahati,et al.  Role of antigen-specific regulatory CD4+CD25+ T cells in tolerance induction after neonatal IP administration of AAV-hF.IX , 2013, Gene Therapy.

[21]  M. Tuchman,et al.  Clinical outcomes of neonatal onset proximal versus distal urea cycle disorders do not differ. , 2013, The Journal of pediatrics.

[22]  Lili Wang,et al.  Hepatic gene transfer in neonatal mice by adeno-associated virus serotype 8 vector. , 2012, Human gene therapy.

[23]  H. Morizono,et al.  Sustained Correction of OTC Deficiency in Spf ash mice Using Optimized Self-complementary AAV2/8 Vectors , 2011, Gene Therapy.

[24]  Lili Wang,et al.  AAV8-mediated hepatic gene transfer in infant rhesus monkeys (Macaca mulatta). , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[25]  M. R. Delgado Alvira,et al.  Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale. , 2010, Human gene therapy.

[26]  R. Herzog,et al.  Hepatic gene transfer as a means of tolerance induction to transgene products. , 2009, Current gene therapy.

[27]  I. Alexander,et al.  Gene Delivery to the Juvenile Mouse Liver Using AAV2/8 Vectors. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[28]  H. Morizono,et al.  Long-term correction of ammonia metabolism and prolonged survival in ornithine transcarbamylase-deficient mice following liver-directed treatment with adeno-associated viral vectors. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[29]  R. Jessberger,et al.  Precise hit: adeno-associated virus in gene targeting , 2005, Nature Reviews Microbiology.

[30]  T. Daly.  AAV-mediated gene transfer to the liver. , 2004, Methods in molecular biology.

[31]  Lili Wang,et al.  Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[32]  H. Morizono,et al.  Expression of Wild-Type and Mutant Human Ornithine Transcarbamylase Genes in Chinese Hamster Ovary Cells and Lack of Dominant Negative Effect of R141Q and R40H Mutants , 2000, Pediatric Research.

[33]  Expression, purification and kinetic characterization of wild-type human ornithine transcarbamylase and a recurrent mutant that produces 'late onset' hyperammonaemia. , 1997, The Biochemical journal.

[34]  A. Moorman,et al.  Development of the ornithine cycle in rat liver: Zonation of a metabolic pathway , 1996, Hepatology.

[35]  L. Rosenberg,et al.  The spfash mouse: a missense mutation in the ornithine transcarbamylase gene also causes aberrant mRNA splicing. , 1989, Proceedings of the National Academy of Sciences of the United States of America.